Gilead Pursues Cancer, Inflammation as Next Step to Diversify Beyond HIV

Gilead Sciences has heard it all before — it has an awesome cash machine going in the HIV drug business, but it won’t last forever, and it has never really diversified well into other disease categories.
Xconomy